EUVIMEDEUVIMED entdecken
Crossref

Toosendanin inhibits osteoclast formation and alleviate postmenopausal osteoporosis by regulating the p38 signaling pathway

Tingting Tan, Tao Li, Cheng Xiang, Zhengxiao Ouyang

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.109745 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Tingting Tan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011 Hunan, PR China; Department of Immunology, School …. Hauptthemen laut MEDLINE: Osteoporosis, Postmenopausal, Osteoporosis, Bone Resorption. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disruption of the balance between osteoclasts and osteoblasts could lead to bone diseases including osteoporosis. It's well known that RANKL-RANK signaling plays a vital role in activating osteoclasts. Herein, we explored the therapeutic effects of toosendanin (TSN) in osteoporosis, showing that TSN attenuated RANKL-stimulated osteoclastogenesis and osteoclast-specific gene expression in vitro. Bioinformatics predicted that TSN could interfere p38 subunits and regulate the MAPK cascade, and we further verified and demonstrated that TSN significantly inhibited RANKL-induced p38 signaling through western blot. In ovariectomized mouse model, TSN effectively inhibited the formation of TRAP-positive osteoclasts and exhibited protective effect against bone loss. Altogether, these data indicate that TSN targeted p38 activation to inhibit osteoclastogenesis, suggesting the possible therapeutic use of TSN in osteoporosis in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Osteoporosis, PostmenopausalOsteoporosisBone ResorptionHumansAnimalsMiceFemaleOsteoclastsSignal TransductionOsteogenesisRANK LigandCell DifferentiationNFATC Transcription FactorsTriterpenes

Stichwörter der Autor:innen

MAPK signalingOsteoclastOsteoporosisP38Toosendanin

Substanzen

RANK LigandNFATC Transcription FactorstoosendaninTriterpenes

Autor:innen und Institutionen

  • Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011 Hunan, PR China; Department of Immunology, School of Basic Medical Science, Central South University, Changsha, Hunan, P…
  • Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011 Hunan, PR China. Electronic address: 847092010@qq.com.
  • Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011 Hunan, PR China. Electronic address: chengxiang96@csu.edu.cn.
  • Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011 Hunan, PR China. Electronic address: ouyangzhengxiao@csu.edu.cn.

Zitieren

APA

Tan, T., Li, T., Xiang, C., & Ouyang, Z. (2023). Toosendanin inhibits osteoclast formation and alleviate postmenopausal osteoporosis by regulating the p38 signaling pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.109745

Vancouver

Tan T, Li T, Xiang C, Ouyang Z. Toosendanin inhibits osteoclast formation and alleviate postmenopausal osteoporosis by regulating the p38 signaling pathway. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.109745

BibTeX
@article{Tan2023,
  author = {Tan, Tingting and Li, Tao and Xiang, Cheng and Ouyang, Zhengxiao},
  title = {Toosendanin inhibits osteoclast formation and alleviate postmenopausal osteoporosis by regulating the p38 signaling pathway},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.109745}
}
Kostenlos starten →